Merry Life Biomedical Advances Global Phase 2 Trial of TML-6 for Early Alzheimer's Disease
Merry Life Biomedical has advanced its global Phase 2 trial of TML-6, an oral therapeutic targeting cellular protein clearance in early Alzheimer's disease across 20 international sites.
Wall Street Correspondent
TAIPEI — Merry Life Biomedical advanced its global Phase 2 clinical trial of TML-6, an oral therapeutic candidate targeting cellular protein clearance in early Alzheimer's disease, according to a PR Newswire release published Sept. 21, 2026.
Strategic Context
The multinational study spans 20 clinical sites across three distinct geographic regions. The trial incorporates nine medical centers in Taiwan, seven sites in Sweden, and four centers in the United States.
TML-6 is designed as an oral therapy that focuses on autolysosomal biology. The trial protocol evaluates the candidate's mechanism in clearing cellular proteins associated with the progression of early Alzheimer's disease.
Forward Outlook
Operators, licensing partners, and clinical allocators tracking the Alzheimer's therapeutics pipeline will monitor patient recruitment milestones and safety data emerging from the multi-region trial sites across Taiwan, Sweden, and the United States.
Sophia Brennan
Wall Street Correspondent
Covers IPOs, buybacks, and the capital-markets calendar out of New York.
